N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use
View Patent ↗In its many embodiments, the present invention provides certain substituted N-aryl and N-heteroaryl piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , L, R 4 , L 1 , Q, R 5 and R 6 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, may be useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
1. A compound having the structural Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
X is selected from —N— and —CH—;
R 1 is selected from H, methyl, and halogen;
R 2 is selected from H, halogen, cyano, cyclopropyl, —CH 3 , and —OCH 3 ;
R 4 is selected from H, halogen, and methyl;
-L- is a divalent moiety —C(O)—;
R 3 is —N(R N1 )(R N2 ), wherein:
R N1 is selected from H and —(C 1 -C 6 )alkyl; and
R N2 is selected from H, —(C 1 -C 6 )alkyl, cyclopropyl, —O—(C 1 -C 6 )alkyl, —OH, halogen, —CN, and —(C 1 -C 6 )alkyl which is substituted with 1 or 2 groups independently selected from:
—OH, halogen, —CN,
optionally substituted phenyl, (wherein said optional substitutents on said phenyl are 1 to 3 groups independently selected from OH, CN, —(C 1 -C 4 )alkyl, —(C 1 -C 4 )alkoxyl),
optionally substituted heteroaryl, (wherein said optional substituents on said heteroaryl are 1 to 3 groups independently selected from —(C 1 -C 6 )alkyl, —(C 1 -C 4 )alkoxyl, and cyclopropyl),
optionally substituted cyclopropyl (wherein said optional substituents on said cyclopropyl are 1 to 3 groups independently selected from —(C 1 -C 6 )alkyl), and
optionally substituted heterocycloalkyl (wherein said optional substitutents on said heterocycloalkyl are 1 to 3 groups independently selected from halogen, —OH, oxo, CN, and —(C 1 -C 6 )alkyl,
or, alternatively, R N1 and R N2 are taken together with the nitrogen atom to which they are shown attached to form a 4-, 5-, or 6-membered fully saturated heterocyclic ring comprising (including the nitrogen atom) 1, 2, or 3 ring heteroatoms selected from N, N-oxide, O, S, and S-oxide,
wherein said heterocyclic ring is unsubstituted or substituted with 1, 2, or 3 substituents independently selected from halogen, —OH, oxo, CN, —(C 1 -C 6 )alkyl, amino-substituted —(C 1 -C 6 )alkyl (wherein said amino is 1, 2, or 3 groups independently selected from —NH 2 , —N(C 1 -C 4 alkyl) 2 , and —NH(C 1 -C 4 alkyl)), —O—(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkyl-OH, —(C 1 -C 6 )haloalkyl, —C(O)O—(C 1 -C 6 )alkyl, cyclopropyl, spirocyclopropyl, —CH 2 —NHC(O)O—(C 1 -C 6 )alkyl, —CH 2 —N(CH 3 )C(O)O—(C 1 -C 6 )alkyl, phenyl, benzyl, —NHC(O)-phenyl, heteroaryl, —(C 1 -C 4 )alkylheteroaryl, and heterocycloalkyl;
-L 1 - is a divalent moiety selected from:
wherein the wavy line indicates point of attachment for L1 to the rest of the compound;
Q is a bond or a divalent moiety selected from —C(O)—, and —C(O)O—; and
R 5 is selected from:
—C(R 5A )(R 5B )(R 5C ), wherein:
each of R 5A , R 5B and R 5C is independently selected from: H, halogen, NH 2 , NHCH 3 , OH, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )alkenyl, —(C 1 -C 6 )alkynyl, —(C 3 -C 6 )cycloalkyl, —(C 3 -C 6 )cycloalkyl substituted with —(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkenyl, —(C 1 -C 6 )alkynyl, phenyl, phenyl substituted with from 1 to 3 groups independently selected from halogen, OH, —NH 2 , —(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )alkyl, cyclopropyl, —O—(C 1 -C 6 )haloalkyl, —O-cyclopropyl, and —C(O)O—(C 1 -C 6 )alkyl,
wherein n is an integer from 1 to 4;
wherein R 5D is selected from H, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, phenyl, and phenyl substituted with from 1 to 3 groups independently selected from OH, halogen, —(C 1 -C 6 )alkyl, and —O—(C 1 -C 6 )alkyl, and
phenyl, wherein:
said phenyl is unsubstituted or substituted with 1, 2, or 3 groups independently selected from halogen, CN, —(C 1 -C 6 )alkyl, and —(C 1 -C 6 )haloalkyl; and
R 6 is H or CH 3 .
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is N.
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is CH.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from H, methyl, F, and Cl.
5. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from H, Cl, cyano, cyclopropyl, —CH 3 , and —OCH 3 .
6. The compound of claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 4 is H, —CH 3 , or chloro.
7. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein L is —C(O)—.
8. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein R 3 is —N(R N1 )(R N2 ), wherein:
R N1 is selected from H and —(C 1 -C 6 )alkyl; and
R N2 is selected from H, —(C 1 -C 6 )alkyl, cyclopropyl, —O—(C 1 -C 6 )alkyl, —OH, halogen, —CN, and —(C 1 -C 6 )alkyl which is substituted with 1 or 2 groups independently selected from:
—OH, halogen, —CN,
optionally substituted phenyl, (wherein said optional substitutents on said phenyl are 1 to 3 groups independently selected from OH, CN, —(C 1 -C 4 )alkyl, —(C 1 -C 4 )alkoxyl),
optionally substituted heteroaryl, (wherein said optional substituents on said heteroaryl are 1 to 3 groups independently selected from —(C 1 -C 6 )alkyl, —(C 1 -C 4 )alkoxyl, and cyclopropyl),
optionally substituted cyclopropyl (wherein said optional substituents on said cyclopropyl are 1 to 3 groups independently selected from —(C 1 -C 6 )alkyl), and
optionally substituted heterocycloalkyl (wherein said optional substitutents on said heterocycloalkyl are 1 to 3 groups independently selected from halogen, —OH, oxo, CN, and —(C 1 -C 6 )alkyl.
9. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein:
R 3 is —N(R N1 )(R N2 ), wherein:
R N1 is selected from H, methyl, and ethyl; and
R N2 is H, methyl, ethyl, —O-methyl, —O-ethyl, OH, fluoro, chloro, —CN, substituted methyl, or substituted ethyl, wherein each said substituent is 1 or 2 groups independently selected from:
OH, fluoro, chloro, —CN,
optionally substituted phenyl, (wherein said optional substitutents on said phenyl are 1 to 3 groups independently selected from OH, CN, methyl, ethyl, —O-methyl, and —O-ethyl),
optionally substituted heteroaryl, (wherein said optional substituents on said heteroaryl are 1 to 3 groups independently selected from methyl, ethyl, —O-methyl, —O-ethyl, and cyclopropyl),
optionally substituted cyclopropyl (wherein said optional substituents on said cyclopropyl are 1 to 3 groups independently selected from methyl and ethyl,
optionally substituted heterocycloalkyl (wherein said optional substitutents on said heterocycloalkyl are 1 to 3 groups independently selected from halogen, —OH, oxo, CN, methyl, and ethyl,
—O-methyl, —O-ethyl, —OH, F, Cl, and —CN.
10. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein:
R 3 is —N(R N1 )(R N2 ), wherein R N1 and R N2 are each independently selected from H, methyl, ethyl, n-propyl, i-propyl, —CH 2 CH 2 —OH, cyclopropyl, —CH 2 -oxadiazolyl, —CH 2 -triazolyl, wherein said oxadiazolyl and said triazolyl are each optionally substituted with methyl or cyclopropyl.
11. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein:
L is —C(O)—; and R 3 is —N(CH 3 ) 2 or —NH(CH 3 ).
12. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein:
R 3 is —N(R N1 )(R N2 ), wherein R N1 and R N2 are taken together with the nitrogen atom to which they are shown attached to form a 4-, 5-, or 6-membered fully saturated heterocyclic ring comprising (including the nitrogen atom) 1, 2, or 3 ring heteroatoms selected from N, N-oxide, O, S, and S-oxide,
wherein said heterocyclic ring is unsubstituted or substituted with 1, 2, or 3 substituents independently selected from halogen, —OH, oxo, CN, —(C 1 -C 6 )alkyl, amino-substituted —(C 1 -C 6 )alkyl (wherein said amino is 1, 2, or 3 groups independently selected from —NH 2 , —N(C 1 -C 4 alkyl) 2 , and —NH(C 1 -C 4 alkyl)), —O—(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkyl-OH, —(C 1 -C 6 )haloalkyl, —C(O)O—(C 1 -C 6 )alkyl, cyclopropyl, spirocyclopropyl, —CH 2 —NHC(O)O—(C 1 -C 6 )alkyl, —CH 2 —N(CH 3 )C(O)O—(C 1 -C 6 )alkyl, phenyl, benzyl, —NHC(O)-phenyl, heteroaryl, and —(C 1 -C 4 )alkylheteroaryl, heterocycloalkyl.
13. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein:
R 5 is —C(R 5A )(R 5B )(R 5C ),
wherein each of R 5A , R 5B and R 5C is independently selected from H, F, Cl, OH, NH 2 , NHCH 3 , —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )alkenyl, —(C 1 -C 6 )alkynyl, —(C 3 -C 6 )cycloalkyl, —(C 3 -C 6 )cycloalkyl substituted with —(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkenyl, —(C 1 -C 6 )alkynyl, phenyl, phenyl substituted with from 1 to 3 groups independently selected from F, Cl, —(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )alkyl, and —C(O)O—(C 1 -C 6 )alkyl.
14. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein:
R 5 is —C(R 5A )(R 5B )(R 5C ), wherein:
R 5A is OH;
R 5B is —(C 1 -C 3 )fluoroalkyl; and
R 5C is selected from the group consisting of NH 2 , NHCH 3 , —(C 1 -C 6 )alkyl, —(C 1 -C 4 )fluoroalkyl, phenyl, (wherein said phenyl substituted with from 1-3 groups independently selected from halogen —(C 1 -C 6 )alkyl, and —(C 1 -C 6 )alkoxy), cyclopropyl (wherein said cyclopropyl is optionally substituted with —(C 1 -C 6 )alkyl), cyclobutyl, wherein said cyclobutyl is optionally substituted with —(C 1 -C 6 )alkyl, ethenyl, and ethynyl.
15. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein:
R 5 is a moiety selected from
wherein n is an integer from 1 to 4,
wherein R 5D is selected from H, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, phenyl, and phenyl substituted with from 1 to 3 groups independently selected from OH, F, Cl, methyl, ethyl, n-propyl, i-propyl, —O-methyl, and —O-ethyl.
16. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein:
R 5 is phenyl, wherein said phenyl is unsubstituted or substituted with 1, 2, or 3 groups independently selected from halogen, CN, —(C 1 -C 6 )alkyl, and —(C 1 -C 6 )haloalkyl.
17. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein:
Q is selected from a bond, —C(O)—, and —C(O)O—.
18. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, said compound selected from:
19. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.